Home Featured Page 218

Featured

Latest

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst...

Wesana Health Announces Closing of PsyTech Acquisition

Levitee Labs Commences Trading in U.S. Under Ticker LVTTF

CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development

Red Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering...

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

No, VR Will Not Give You A Psychedelic Trip

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year...

Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Glutamate’s Role in Rapidly-Acting Antidepressants

1...217218219...296 Page 218 of 296

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst...

Wesana Health Announces Closing of PsyTech Acquisition

Levitee Labs Commences Trading in U.S. Under Ticker LVTTF

CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development

Red Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering...

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

No, VR Will Not Give You A Psychedelic Trip

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year...

Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Glutamate’s Role in Rapidly-Acting Antidepressants

EDITOR PICKS

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY